Liposomal pegilated doxorubicin in pediatric patients with bone sarcomas and soft tissue sarcomas: Preliminary report.

e20000 Background: Liposomal pegilated doxorubicinwas designed to increase the therapeutic efficacy and decrease the cardiotoxicity. Methods: Pediatric patients with bone sarcomas and soft tissue sarcomas treated with liposomal pegilated doxorubicin as part of their treatment program are included. A dose of 40 mg/m2 was used and escalated to 10 mg/m2 per course until reaching 50 mg/m2 in patients with rhabdomyosarcoma and Ewing sarcoma. In patients with osteosarcoma the top dose was 60 mg/m2. Twenty-four hours prior to the administration of the anthracycline the patients were premedicated with ranitidine, dexamethasone and cloropiramine. The pegilated doxorubicin was diluted in 400 ml/m2 of dextrose 5% solution and administered as IV infusion in 3 hours. The doxorubicin was administered every 4-6 weeks depending upon the tumor protocol. All the patients had an initial and subsequent evaluation including routine laboratory tests, chest CT scan, electrocardiogram and echocardiogram. Results: 16 patients fro...